SuperworthCytomX Therapeutics market cap CTMX
Share price times shares outstanding: what the whole company sells for, since 2015.
- Today, Oct 23, 2026
- $505.5M
- Highest close in our data
- $1.3B
- Mar 2018
CytomX Therapeutics is worth $505.5M at the close on Oct 23, 2026, at $2.32 a share.
That is down 6% over the last year and up 31% over five years.
Its highest close in our data was $1.3B in Mar 2018.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $505.5M | $496.8M | $964.1M | −32% |
| 2025 | $743.8M | $36.5M | $743.8M | +788% |
| 2024 | $83.7M | $69.7M | $300M | −19% |
| 2023 | $103.8M | $71.4M | $189M | −2% |
| 2022 | $105.7M | $82.4M | $287.1M | −63% |
| 2021 | $282.5M | $275.4M | $606.4M | −7% |
| 2020 | $302.8M | $225.6M | $653.9M | −22% |
| 2019 | $388M | $243.5M | $857.8M | −42% |
| 2018 | $673.8M | $595.9M | $1.3B | −17% |
| 2017 | $810.8M | $405.2M | $871.5M | +103% |
| 2016 | $400.1M | $333.8M | $569M | −47% |
| 2015 | $751.8M | $689.1M | $852.3M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest CytomX Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| CTMXCytomX Therapeutics | $505.5M |
| ARVNArvinas | $477.3M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| COLLCollegium Pharmaceutical | $747.5M |
| ABUSArbutus Biopharma | $831M |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| NATRNatures Sunshine Products | $213.8M |
| OMEROmeros | $1.2B |
| Peer median | $597.2M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on CytomX Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.